Abstracts tagged "clinical trials and lipids"

Abstract Number: 943 • ACR/ARP Annual Meeting 2019

A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

Sarfaraz Hasni¹, Sarthak Gupta ², Michael Davis ³, Elaine Poncio ⁴, Yenealem Temesgen-Oyelakin ⁴, Phillip Carlucci ⁴, Xinghao Wang ⁴, Mohammad Naqi ⁴, Martin Playford ⁵, Rishi Goel ⁴, Xiaobai Li ⁶, Ann Biehl ⁴, Isabel Ochoa-Navas ⁴, Zerai Manna ⁴, Yinghui Shi ⁷, Don Thomas ⁸, Jinguo Chen ⁹, Angélique Biancotto ⁹, Richard Apps ⁹, Foo Cheung ⁹, Yuri Kotliarov ⁹, Ashley Babyak ⁶, Katie Stagliano ⁹, John Tsang ⁹, Wanxia Tsai ¹⁰, Laura Vian ¹⁰, Nathalia Gazaniga ⁴, Valentina Giudice ⁴, Stephen Brooks ¹¹, Meggan Mackay ¹², Peter Gregersen ¹³, Betty Diamond ¹⁴, Nehal Mehta ¹⁵, Alan Remaley ⁵, John O'Shea ¹⁶, Massimo Gadina ¹⁰ and Mariana Kaplan ¹⁶, ¹National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, ³NIAMS/NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, ⁵NHLBI/NIH, Bethesda, ⁶Clinical Center/NIH, Bethesda, ⁷Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹NIAID/NIH, Bethesda, ¹⁰Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ¹¹Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ¹²Feinstein Institute for Medical Research, New York, ¹³Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁴Feinstein Institutes of Medical Research, Manhasset, NY, ¹⁵National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ¹⁶National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda